Esomeprazole: Pharmacology and development of a new proton pump inhibitor;Ésoméprazole: Pharmacologie et développement d'un nouvel inhibiteur de pompe à protons

Hepato-Gastro

Volumn 10, Issue 4, 2003, Pages 281-295

  Scarpignato, Carmelo ^a   Pelosini, Iva ^a   Lamarque, Dominique ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CHIRALITY; DRUG ACTIVITY; HUMAN; ISOMER; PHARMACODYNAMICS; REVIEW; STOMACH ACID SECRETION; TREATMENT INDICATION;

EID: 0042476484     PISSN: 12537020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Stedman CAM, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.
2. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
3. Kakinoki B, Ono C, Yamazaki N, Chikamatsu N, Wakatsuki D, Uchiyama K, Morinaka Y. General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl] sulfinyl]-1H-imidazo [4,5 b] pyridine. Methods Find Exp Clin Pharmacol 1999; 21: 179-87.
4. Anonymus. Tenatoprazole. Benatoprazole, TU 199. Drugs R & D 2002; 3: 276-7.
5. +-ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305.
6. Wolfe, MM, Sachs, G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118 (2 suppl 1): S9-31.
7. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
8. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661-5.
9. Salas M, Ward A, Caro J. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 2002; 15; 2: 17-23.
10. Scarpignato C, Pelosini I. Antisecretor drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. Progr Basic Clin Pharmacol 1999; 11: 136-80.
11. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-28.
12. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs double dose of a proton pump inhibitor in triple therapy for Helicobacter pylari eradication: a meta-analysis. Aliment Pharmacol Ther 2002; 16: 1149-56.
13. Malfertheiner P, Mégraud F, O'Morain C, Hungin APS, Jones R, Axon A, Graham DY, Tytgat G & the European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002; 16: 167-80.
14. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Jensen RT. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 1993; 17: 468-80.
15. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison. Front Gastrointest Res 1995; 23: 240-57.
16. 2-antagonist refractory ulcers. Digestion 1989; (suppl 1): 31-9.
17. Bell N, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (suppl 1): 59-67.
18. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24.
19. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112: 1798-810.
20. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review). Cochrane Database Syst Rev 2001; CD002095.
21. Scarpignato C, Pelosini I. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol 1999; 31 (suppl 1): S63-72.
22. Brown GJ, Yeomans ND. Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: the role of proton pump inhibitors. Drug Saf 1999; 21: 503-12.
23. 2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 (suppl 1): 9-14.
24. 2 de l'histamine. Gastroenterol Clin Biol 1999; 23: S78-89.
25. Wilder-Smith CH, Merki HS. Tolerance during dosing with H2-receptor antagonists. An overview. Scand J Gastroenterol 1992; 27 (suppl 193): 14-9.
26. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion: tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013-8.
27. 2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 200; 15: 1291-9.
28. Earnest D, Robinson M, Rodriguez-Stanley S, Ciociola AA, Jaffe P, Silver MT, et al. Managing heartburn at the « base » of the GERD « iceberg »: effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther 2000; 14: 911-8.
29. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB Jr, et al. Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn. Aliment Pharmacol Ther 2001; 15: 1365-74.
30. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 9: 763-7.
31. 2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6.
32. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
33. Cross LB, Justice LN. Combination drug therapy for gastroesophageal reflux disease. Ann Pharmacother 2002; 36: 912-6.
34. McColl KEL, Kennerley P. Proton pump inhibitors - differences emerge in the hepatic metabolism. Digest Liver Dis 2002; 34: 461-7.
35. Thomson ABR. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2: 482-93.
36. Langman MJS. Which PPI? Gut 2001; 49:309-10.
37. Kromer W, Horbach S Lühmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: 57-77.
38. Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NICE, UK: Technology Appraisal Guidance n° 7, 2000 (http://www.NICE.org.uk).
39. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993; 7 (suppl 1): 13-31.
40. Amin MR, Postma GN, Johnson P, Digges N, Koufman JA. Proton pump inhibitor resistance in the treatment of laryngopharyngeal reflux. Otolaryngol Head Neck Surg 2000; 125: 374-8.
41. Sontag SJ. Persistent gastroesophageal reflux disease symptoms on standard proton-pump inhibitor therapy. Gastroenterol Clin North Am 2002; 31 (4 suppl): S77-84.
42. Galmiche JP, Sacher-Huvelin S. Reflux gastro-œsophagien résistant aux inhibiteurs de la pompe à protons. Hépato-Gastro 2002; 9: 159-63.
43. Ashida K, Sakaguchi M, Tanaka M, Takiuchi H, Egashira Y, Katsu K. Clinical study on the pathophysiology and treatment of PPI-resistant ulcers. J Clin Gastroenterol 1995; 20 (suppl 2): S67-71.
44. Katz PO. Lessons learned from intragastric pH monitoring. J Clin Gastroenterol 2001; 33: 107-13.
45. Hatlebakk JG, Katz PO, Castell DO. Medical therapy: management of the refractory patient. Gastroenterol Clin North Am 1999; 28: 847-60.
46. Leite L, Lambrecht N, Sachs G, et al. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump? Gastroenterology 1995; 108: A147.
47. 2-receptor antagonists after oméprazole failure: report of two cases. Am J Gastroenterol 1995; 90: 1874-7.
48. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
49. Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 2001 May; 13 (suppl 1): S29-33.
50. Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001; 13 (suppl 1): S43-47.
51. Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 2001; 13 (suppl 1): S35-41.
52. Parsons ME, Garner A. Review article: drug development in gastroenterology: the changing view of industry. Aliment Pharmacol Ther 1995; 9: 457-63.
53. Hassan-Alin M, Niazi M, Röhss K, Sthenoff H. Esomeprazole, the Sisomer of omeprazole, is optically stable in humans. Gastroenterology 2000; 118 (suppl 2): A1244-5.
54. The Nobel Foundation. Information for the Public. The 2001 Nobel Prize in Chemistry [http://www.nobel.se/chemistry/laureates/2001/public.htlm].
55. Cotton H, Elebring T, Larsson M, Li L, Sörensen H, von Unge S. Asymmetric synthesis of esomeprazole. Tetrahedron: Asymmetry 2000; 11: 3819-25.
56. Lough JW, Wainer I. Chirality in natural and applied sciences. Blackwell Publishing, Oxford 2002: 1-336.
57. Stern L. The lesson of thalidomide. Clin Pharmacol Ther 1973; 14: 660-1.
58. Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002; 53: 629-57.
59. Williams K, Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985; 30: 333-54.
60. Lam Y. Stereoselectivty: an issue of significant importance in clinical pharmacology. Pharmacotherapy 1988; 8: 147-57.
61. Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs 1996; 52 (suppl 57): 1-12.
62. Lee EJ, Williams KM. Chirality. Clinical pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 1990; 18: 339-45.
63. Pifferi G, Perucca E. The cost benefit ratio of enantiomeric drugs. Eur J Drug Metab Pharmacokinet 1995; 20: 15-25.
64. Eichelbaum M. Enantiomers: implications and complications in developmental pharmacology. Dev Pharmacol Ther 1992; 18: 131-4.
65. Brocks DR, Jamali F. Stereochemical aspects of pharmacotherapy. Pharmacotherapy 1995; 15: 551-64.
66. Scott AK. Stereoisomers and drug toxicity. The value of single stereoisomer therapy. Drug Saf 1993; 8: 149-59.
67. Hsu WH. Toxicity and drug interactions of levamisole. J Am Vet Med Assoc 1980; 176: 1166-9.
68. Marzo A, Cardace G, Arrigoni Martelli E. Enzymes in stereoselective pharmacokinetics of endogenous substances. Chirality 1992; 4: 247-51.
69. Erlandsson P, Isaksson R, Lorentzon P, Lindberg P. Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase. The effect of the enantiomers of oméprazole on gastric glands. J Chromatogr 1990; 532: 305-19.
70. Kromer W. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. Scand J Gastroenterol 2001; 36 (suppl 234): 3-9.
71. Eichelbaum M. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem Pharmacol 1988; 37: 93-6.
72. Tucker GT, Lennard MS. Enantiomer specific pharmacokinetics. Pharmacol Ther 1990; 45: 309-29.
73. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors-focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
74. Egan LJ, Murray JA. New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors. Dig Dis 2000; 18: 58-63.
75. Tybring G, Bottiger Y, Widen J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 1997; 62: 129-37.
76. Äbelö A, Andersson TB, Bredberg U, Skanberg I, Weidolf L. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole. Drug Metab Dispos 2000; 28: 58-64.
77. Andersson T, Bredberg E, Sunzel M, Antonsson M, Weidolf L. Pharmacokinetics and Effect Pentagastrin stimulated peak acid output of omeprazole and its two optical isomers, S-omeprazole/esomeprazole and R-omeprazole. VII World Conference on Clinical Pharmacology and Therapeutics, Florence, Italy, July 15-20, 2002: 241 (abstract 935).
78. Junghard O, Hassan-Alin M, Hasselgren, G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of ésoméprazole on intragastric pH. Eur J Clin Pharmacol 2002; 58: 453-8.
79. Tonini M, Vigneri S, Savarino V, Scarpignato C. Clinical pharmacology and safety profile of ésoméprazole, the first enantiomerically pure proton pump inhibitor. Dig Liv Dis 2001; 33: 600-6.
80. Vigneri S, Tonini M, Scarpignato C, Savarino V. Improving opportunities for effective management of gastro-esophageal reflux disease. Dig Liv Dis 2001; 33: 720-30.
81. Kale-Pradhan PB, Landry HK, Sypula WT. Ésomeprazole for acid peptic disorders. Ann Pharmacother 2002; 36: 655-63.
82. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62: 1503-38.
83. Lundborg P. Investigator's brochure on esameprazole for oral use. 5th Edition, AstraZeneca R&D Mölndal, Sweden, 2002.
84. Andersson T, Bredberg E, Sunzel M, Antonsson M, Weidolf L. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-oméprazole (R-O). Gastroenterology 2000; 118 (suppl 2): A1210.
85. Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990; 19: 141-53.
86. Robinson M. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999; 13 (suppl 5): 5-10.
87. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411-26.
88. Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esoméprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665-70.
89. Nexium® (esomeprazole). Product Information. AstraZeneca. February 2001.
90. Andersson T, Magner DJ, Patel JB, Rogers P, Levine JG. Esomeprazole 40 mg capsules are bioequivalent when administered intact or as the contents mixed with applesauce. Clin Drug Investigat 2001; 21: 67-71.
91. White CM, Kalus JS, Quercia R, Fortier C, Piotrowski A, Roach A, Sostek MB. Delivery of esomeprazole magnesium enteric-coated pellets through small caliber and standard nasogastric tubes and gastrostomy tubes in vitro. Am J Health Syst Pharm 2002; 59: 2085-8.
92. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 38-49.
93. Lind T, Rydberg L, Kylebäck A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Röhss K. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.
94. Sjövall H, Bjornsson E, Holmberg J, Hässelgren G, Rohss K, Hassan-Alin M. Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 2002; 14: 491-6.
95. Hässelgren G, Hassan-Alin M, Andersson T, Claar-Nilsson C, Rohss K. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001; 40: 145-50.
96. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999; 45: 243-53.
97. Naesdal J, Andersson T, Bodemar G, Lorsson R, Regardh CG, Skonberg I, Walan A. Pharmacokinetics of [14C] omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986; 40: 344-51.
98. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 523-37.
99. Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13 (suppl 3): 18-26.
100. Paulsen O, Höglund P, Walder M. No effect of omeprazole induced hypoacidity on the bioavailability of amoxycillin or bacampicillin. Scand J Infect Dis 1989; 21: 219-23.
101. Creutzfeldt W, Stockmann F, Conlon JM, Folsch UR, Bonatz G, Wulfrath M. Effect of short- and long-term feeding with omeprazole on rat gastric endocrine cells. Digestion 1986; 35 (suppl 1): 84-95.
102. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric acid secretion. Digestion 1986; 35: 42-55.
103. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. Use of proton inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 2002; 47: 1526-9.
104. Kallen BA. Use of oméprazole during pregnancy - no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 96: 63-8.
105. Arnold R. Safety of proton pump inhibitors - an overview. Aliment Pharmacol Ther 1994; (suppl 1): 65-70.
106. Freston JW. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 1997; 92 (suppl): S51-55.
107. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56 (suppl 4): S11-17.
108. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Esoméprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
109. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophogitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
110. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
111. Laine L. Esomeprazole in the treatment of Helicobacter pylori. Aliment Pharmacol Ther 2002; 16 (suppl 4): 115-8.
112. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining heoled erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27-34.
113. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-35.
114. Maton PN, Vakil NB, Levine JG, Hwang C, Skammer W, Lundbor P. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001; 24: 625-35.
115. Svoboda AC. Increasing concerns about chronic proton pump inhibitor use. J Clin Gastroenterol 2001; 33: 3-10.
116. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Potential gostrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-68.
117. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205-13.
118. Genta RM, Magner DJ, D'Amico D, Levine DS. Safety of long-term treatment with a new PPI, esomeprazole in GERD patients. Gastroenterology 2000; 118 (suppl 2): A16.
119. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002; 25: 263-86.
120. Tonini M, De Ponti F, Di Nucci A, Crema F. Cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999; 13: 1585-91.
121. Hässelgren B, Claar-Nilsson C, Hasselgren G, Niazi M, Svernhage E. Studies in healthy volunteers do not show any electrocardiographic effects of esomeprazole. Clin Drug Invest 2000; 6: 425-31.
122. Rawlins MD, Jefferys DB. United Kingdom Product Licence applications involving new active substances, 1987-1989: their fate after appeals. Br J Clin Pharmacol 1993; 35: 599-602.
123. Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Safety 1996; 5: 363-75.
124. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1729-36.
125. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J Drug Ass 2002; 5: 165-78.
126. Peterson WL. Improving management of GERD: evidence-based therapeutic strategies. AGA Press, Bethesda, 2002: 1-28.